Lyell Immunopharma (LYEL) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Lyell Immunopharma (NASDAQ: LYEL):

• 11/3/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.
• 10/25/2026 – Lyell Immunopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/17/2026 – Lyell Immunopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/15/2026 – Lyell Immunopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/26/2026 – Lyell Immunopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/12/2026 – Lyell Immunopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/11/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by HC Wainwright.
• 9/11/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock traded up $4.64 during trading on Wednesday, hitting $15.41. 900,718 shares of the stock were exchanged, compared to its average volume of 136,484. Lyell Immunopharma, Inc. has a 12 month low of $7.20 and a 12 month high of $45.00. The stock’s fifty day moving average is $10.85 and its 200 day moving average is $16.77. The stock has a market cap of $377.52 million, a PE ratio of -1.20 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. Sell-side analysts anticipate that Lyell Immunopharma, Inc. will post -7.16 EPS for the current fiscal year.

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.